Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Zacks News
Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More
by Kinjel Shah
Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Catalyst (CPRX) Up 8.9% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y
by Zacks Equity Research
Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.
Catalyst Pharmaceutical (CPRX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and 3.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Spectrum's (SPPI) NSCLC Drug Gets FDA's Fast Track Designation
by Zacks Equity Research
The FDA grants a Fast Track designation to Spectrum Pharmaceuticals' (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.
Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why
by Zacks Equity Research
Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans
by Zacks Equity Research
Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 5.5%
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Why Is Catalyst (CPRX) Up 4.4% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
Why Is Catalyst (CPRX) Down 7.5% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst (CPRX) Eyes Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.
Catalyst's (CPRX) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 12.50% and 2.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst (CPRX) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 11.11% and -8.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Catalyst (CPRX) Up 52.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet
by Zacks Equity Research
Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.